title: Audiometric outcomes of topical IGF1 treatment for sudden deafness refractory to systemic steroids.
abstract: OBJECTIVE
  To examine the effects of topically applied recombinant human insulin-like growth factor 1 (IGF1) via gelatin hydrogels on alterations in pure-tone audiometry (PTA) in patients with sudden sensorineural hearing loss (SSHL) refractory to systemic steroids.
  
  
  METHODS
  Retrospective chart review.
  
  
  METHODS
  A single university hospital.
  
  
  METHODS
  Twenty-five patients with SSHL refractory to systemic steroids who received topical IGF1 treatment.
  
  
  METHODS
  Single topical application of IGF1 to the round window niche using gelatin hydrogels.
  
  
  METHODS
  The primary outcome was alterations in PTA thresholds at frequencies of 0.25, 0.5, 1, 2, and 4 kHz after topical IGF1 application. Secondary outcomes included differences in final improvements in PTA thresholds among frequencies tested and cumulative numbers of patients showing 10- or 20-dB recovery in PTA during the observation period.
  
  
  RESULTS
  Topical IGF1 application via gelatin hydrogels significantly altered PTA thresholds at each frequency tested and at the average frequency. The numbers of patients with a 10-dB recovery in PTA increased until 4 weeks after treatment and then stabilized, whereas those patients showing 20-dB recovery gradually increased during the observation period.
  
  
  CONCLUSIONS
  Topical IGF1 application via gelatin hydrogels contributes to the recovery of PTA levels in patients with SSHL refractory to systemic steroids. Major recovery of PTA levels occurs within 4 weeks after treatment.
authors: Department of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan. tnakagawa@ent.kuhp.kyoto-u.ac.jp
authors: Takayuki
authors: T
authors: Nakagawa
authors: Eriko
authors: E
authors: Ogino-Nishimura
authors: Harukazu
authors: H
authors: Hiraumi
authors: Tastunori
authors: T
authors: Sakamoto
authors: Norio
authors: N
authors: Yamamoto
authors: Juichi
authors: J
authors: Ito
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D001301:Audiometry, Pure-Tone; D001309:Auditory Threshold / Q000187:drug effects; D004351:Drug Resistance; D005260:Female; D006319:Hearing Loss, Sensorineural / Q000188:drug therapy*; D003639:Hearing Loss, Sudden / Q000188:drug therapy*; D006801:Humans; D020100:Hydrogels; D007334:Insulin-Like Growth Factor I / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D012189:Retrospective Studies; D012405:Round Window, Ear; D013256:Steroids / Q000627:therapeutic use; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D020100:Hydrogels; D011994:Recombinant Proteins; D013256:Steroids; D007334:Insulin-Like Growth Factor I